In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone

详细信息    查看全文

• 作者：Ying Su ; Yun-yun Zhan ; Ben-fu Wang ; Si-Cong Wang ; Da-peng Dai ; Guo-xin Hu ; Han Lin ; Qing-quan Lian and Jian-ping Cai
• 刊名：Drug Testing and Analysis
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：9
• 期：2
• 页码：216-220
• 全文大小：184K
• ISSN：1942-7611

文摘

CYP2D6 is an important member of the cytochrome P450 (CYP450) enzyme super family, with at least 100 CYP2D6 alleles being previously identified. Genetic polymorphisms of CYP2D6 significantly influence the efficacy and safety of some drugs, which might cause adverse effects and therapeutic failure. The aim of this study was to clarify the catalytic activities of 24 CYP2D6 alleles on the oxidative in vitro metabolism of methadone. Reactions were incubated with 50–2000  µM methadone for 30 min at 37 °C and terminated by cooling to -80 °C immediately. Methadone and the major metabolite EDDP were analyzed by an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) system. Compared with wild-type CYP2D6*1, most variants showed significantly altered values in V_max and intrinsic clearance (V_max/K_m). Only three variants (CYP2D6*88, *91 and E215K) exhibited markedly increased intrinsic clearance values, and one variant CYP2D6*94 showed no significant difference. On the other hand, the kinetic parameters of two CYP2D6 variants (CYP2D6*92 and *96) could not be determined because they had no detectable enzyme activity, whereas 18 variants exhibited significantly decreased values. To sum up, this study demonstrated that more attention should be paid in clinical administration of methadone to individuals carrying these CYP2D6 alleles. Copyright